The stage is set for the American Heart Association (AHA) Scientific Sessions 2022 to be held November 5-7 at McCormick Place in Chicago, and virtually. Photo credit: Getty Images.
October 4, 2022 — The American Heart Association (AHA) Scientific Sessions 2022 is set for November 5-7 at McCormick Place in Chicago, and virtually. On November 4, a Pre-session Symposia and Early Career Day will take place. The annual meeting will offer broad-ranging, impactful programming which will cover basic, clinical, and population science presented by global thought leaders over three days of results, practical takeaways and meaningful networking.
During the event, awards will be presented Special Lectures, as well as Council Awards covering a range of categories: Named Lectures; Distinguished Achievement; Best Abstract; Early Career Abstract; and Special Recognition. Other meeting features include the Heart Theater, Learning Studios, Early Career/FIT Lounge, and a return of the Puppy Snuggle Zone, among other educational and networking opportunities.
According to AHA program planners, the most highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions, as well as featured science sessions. “Meet the Trialist” will allow participants to connect with featured speakers that are part of these sessions.
AHA Late-Breaking Scientific Session Schedule
Saturday, November 5
“The Main Event: Changing Clinical Practice,” 9:30 a.m. – 10:30 a.m.
TRANSFORM-HF – Comparative Effectiveness of Torsemide versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial
DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension
PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease
“Breakthrough Strategies in the HF Journey,” 3:00 p.m. – 4:00 p.m.
First-in-Human in vivo Crispr/Cas9 Editing of the Ttr Gene by Ntla-2001 in Patients with Transthyretin Amyloidosis With Cardiomyopathy
COACH – A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
PRO-HF – Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial
IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure with Reduced Ejection Fraction
Sunday, November 6
“High Impact Trials in Intervention and Surgery,” 8:00 a.m – 9:00 a.m.
RAPCO – Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials – The 15-Year Clinical Outcomes Comparing Radial Artery with Right Internal Thoracic Artery or With Saphenous Vein Grafting
STRESS – Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The Stress Trial
CTS-AMI – The Impact of Chinese Herbal Medicine, Tongxinluo in Patients with Acute Myocardial Infarction – Results From the CTS-AMI Trial
ECMO-CS – Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results from the Multicenter, Randomized ECMO-CS Trial
“Mindful Disruption of Chronic Hypertension Management,” 3:30 p.m. – 4:30 p.m.
CRHCP: – Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients with Hypertension: A Cluster Randomized Trial
Rich Life Project – Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone: Blood Pressure and Patient-Reported Outcomes
The MB-BP Study – The Effect of Adapted Mindfulness Training in Participants with Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial
QUARTET USA – Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA): A Randomized Controlled Trial
“Changing How we Prevent Cardiovascular and Renal Disease,” 5:00 p.m. – 6:00 p.m.
RESPECT-EPA – Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid
OCEAN(a)-DOSE – Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the Ocean(a)-DOSE Trial
EMPA-KIDNEY – Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial
SPORT – Effect of Low-Dose Statin Compared with Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial
“Drugs and Strategies in ACS and Revascularization,” 5:00 p.m. – 6:00 p.m.
BRIGHT-4 – Bivalirudin With a Post-PCI High-Dose Infusion versus Heparin Monotherapy During Primary PCI in STEMI: The Randomized Bright-4 Trial
OPTION – Efficacy and Safety of Indobufen versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial
PRECISE – Comparison of a Precision Care Strategy with Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The Precise Randomized Trial
ISCHEMIA-EXTENDed – Follow-Up Interim Report
Monday, November 7
“Preventing Limb Loss Through Vascular Interventions and Venous Therapies,” 8:00 a.m. – 9:00 a.m.
BEST-CLI (Clinical) – Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Clinical Results
BEST-CLI (QOL) – Best Endovascular versus Best Surgical Therapy for Patients with Chronic Limb Threatening Ischemia - Quality of Life Analyses
PREVENT-HD – Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients with Covid-19: Primary Results of the PREVENT-HD Randomized Clinical Trial
IMPROVE – A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically-Ill Patients
“Treating Atrial and Supraventricular Arrhythmias,” 11:00 a.m. – 12:00 p.m.
PROGRESSIVE-AF – The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial
RAPID – Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the Rapid Study
NOVA – Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results from the Phase 2 Nova Study
ENHANCE-AF – Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway
“Resistant Hypertension: A Pressure Cooker,” 3:00 p.m. – 4:00 p.m.
FRESH – Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study
PRECISION – Sustained Blood Pressure Lowering Effect with the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results from a Randomized, Controlled Study Including a Withdrawal Phase
BrigHTN: – Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
SPYRAL HTN-ON – Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results from the SPYRAL HTN-ON Med Expansion Randomized Trial
Featured Science Sessions
A total of 44 sessions offered as “Featured Science” are scheduled daily throughout the meeting, and cover the following topics:
- In-depth and Fresh Look at Heart Failure Trials
- New Insights — Cardiac Surgery
- Featured Science in Heart Rhythm Medicine
- Emerging Heart Failure Science
- Evolving Science in COVID-19
- Optimal Management post-PCI/ACS
- Digital Innovations to Improve CVD Prevention
- The Present and Future of Lipid Lowering
AHA and CRF Join Forces
Two leading organizations in cardiovascular disease science, research and education — the American Heart Association (AHA) and the Cardiovascular Research Foundation (CRF) — have joined forces this fall with a unique and forward-thinking alliance. The collaboration began at TCT 2022, held Sept. 16-20 in Boston, MA, and will continue at the AHA 2022 Annual Scientific Meeting. The alliance was established to help strengthen and expand educational opportunities in cardiovascular disease and interventional therapies. At TCT 2022, the AHA presented Best Practices sessions focused on clinical guidelines and vascular care. In turn, CRF will present several sessions at the AHA Scientific Sessions 2022.
“Harnessing the strengths of our two pioneering organizations with extensive experience in translating the latest scientific breakthroughs into practical therapies is crucial,” said the AHA’s Chief Executive Officer Nancy Brown in a written statement. Brown added, “Together, we aim to boost the pace of knowledge, research and expertise within the cardiovascular disease and cardiac interventional therapy communities to help transform cardiovascular care for patients all over the world, particularly as we continue to navigate the COVID-19 pandemic and its still-to-be-uncovered impacts throughout the body and especially the heart.”
“This collaboration will foster innovative research and education by bringing together world-renowned experts in the field to identify and advance the most promising science in cardiology and interventional cardiology,” noted CRF’s President and Chief Executive Officer Juan F. Granada, MD. He added, “The future of our profession and the health of our patients will be brighter because of this collective effort.”
For additional programming and information on the AHA Scientific Sessions 2022:
https://professional.heart.org/es/meetings/scientific-sessions
April 25, 2024 
